Medipo

Simvastatin, the active ingredient in Medipo, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It treats hypercholesterolemia and hyperlipidemia, and is used for primary and secondary prevention of cardiovascular disease.

GNH USA supplies Medipo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Simvastatin is indicated for disorders of lipid metabolism and associated cardiovascular risk. - Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol to lower cardiovascular risk. - Hyperlipidemia: lowers total cholesterol and triglycerides, improving lipid profile. - Primary prevention of cardiovascular disease: decreases the incidence of heart attack and stroke in at‑risk patients. - Secondary prevention of cardiovascular disease: helps prevent recurrent events in patients with established disease.

Simvastatin may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Gastrointestinal upset: includes nausea, abdominal discomfort, or constipation. - Myalgia: muscle aches without significant weakness. - Elevated liver enzymes: mild increases in ALT or AST. - Dizziness: transient sensation of light‑headedness. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to kidney injury. - Hepatotoxicity: significant liver injury with marked enzyme elevation. - Myopathy: muscle weakness with elevated creatine kinase. - Allergic reactions: rash, pruritus, or angioedema. - Severe hypotension: marked drop in blood pressure. - Acute renal failure: kidney dysfunction secondary to muscle breakdown.

Before initiating therapy, several safety considerations are recommended. - Assess liver function: obtain baseline transaminases to detect hepatic disease. - Monitor muscle symptoms: discontinue if severe myalgia or weakness occurs. - Avoid in active liver disease: contraindicated in patients with ongoing hepatic impairment. - Review concomitant medications: identify drugs that affect simvastatin metabolism. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at room temperature: keep in the original container, protect from moisture and heat.

Simvastatin interacts with several medicines that can alter its plasma concentration.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase risk of myopathy. - Gemfibrozil: markedly heightens risk of rhabdomyolysis. - Cyclosporine: raises simvastatin levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Amiodarone: may modestly increase statin concentrations. - Warfarin: can enhance anticoagulant effect, requiring INR monitoring. - Niacin: may increase incidence of muscle toxicity when combined.